E 7449

Drug Profile

E 7449

Alternative Names: E-7449

Latest Information Update: 19 Apr 2017

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Class Antineoplastics
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II B cell lymphoma
  • No development reported Solid tumours

Most Recent Events

  • 01 Apr 2017 Efficacy and phamacokinetic data from a phase I/II trial in B-cell lymphoma presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 24 Sep 2015 No recent reports of development identified - Phase-I/II for Solid tumours in United Kingdom (PO)
  • 17 Oct 2011 Phase-I/II clinical trials in B-cell lymphoma in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top